Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

Masatoshi Kudo; Kazuomi Ueshima; Yasutaka Chiba; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Yasuaki Arai

doi:10.1159/000503032

Related publications

Supplementary Material for: Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yasuharu Sasaki, Keisuke Hino, Takashi Kumada, Kazuhiro Yamamoto, Yoichi Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Yasuaki Arai

Preprint2019

Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial

Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Yasuaki Arai

Article2020

Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial.

Masatoshi Kudo, Kazuomi Ueshima, Chikara Ogawa, Yasutaka Chiba

Article2017

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Riccardo Lencioni, Robert Montal, Ferrán Torres, Joong‐Won Park, Thomas Decaens, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige, Éric Assenat, Yoon‐Koo Kang, Ho-Yeong Lim, Ian Walters, Josep M. Llovet

Journal of Hepatology

Article2015

Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.

Josep M. Llovet, Joong‐Won Park, Ferrán Torres, Thomas Decaens, Éveline Boucher, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, Valérie Boige, Éric Assenat, Yoon‐Koo Kang, Ho-Yeong Lim, Ian Walters, Riccardo Lencioni

Journal of Clinical Oncology